Skip to content

Clinical study to evaluate the safety and efficacy of Body Firming Cream and Under Eye Gel in lactating females and only Under Eye Gel in healthy pregnant females.

An open-label, single-arm study to evaluate the efficacy and safety of a Body Firming Cream and Under Eye Gel in lactating female (post pregnancy mother having 0 month to 36 months old baby) subjects and only Under Eye Gel in healthy pregnant female (1st and 2nd trimester) subjects.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/044565
Enrollment
72
Registered
2022-08-02
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R238- Other skin changes

Interventions

Intervention1: Body Firming Cream: Approx. 4-5 gm of test product to be applied on their hips, buttocks, and thighs and also on legs /abdomen. Product to be used twice daily for a duration of 84 days

Sponsors

Zydus Wellness Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Lactating females a. with diagnosis of cellulite with grades I to III according to Cellulite Severity Grading scale. b. with stage 1 and stage 2 according to Nurnberger-Muller Cellulite Classification Scale c. with Grade 2 and Grade 3 under eyes dark circles and under eyes puffiness as determined by 6-point grading scale. d. Subjects having history of delivery within 42 weeks. 2) Healthy pregnant females a. with Grade 2 and Grade 3 under eyes dark circles and under eyes puffiness as determined by 6-point grading scale. b. Primipara (woman who is giving birth for the first time) subjects, who are diagnosed as pregnant female by gynaecologist.

Exclusion criteria

Exclusion criteria: 1) Subjects having varicose veins or history of phlebitis in the cellulite area or condition such as psoriasis, eczema, erythema, edema, scars, wounds and other visible lesions. 2) Subjects who have used some kind of cellulite-treatment in the last 30 days before beginning of the study or those who underwent any kind of surgical procedure in area of treatment, in past three months before the study. 3) Participation in a similar clinical study within the previous 90 days.

Design outcomes

Primary

MeasureTime frame
1)Dermatological assessment of cellulite of thighs, buttocks and hips using Nurnberger-Muller Scale. 2)Measurement of circumference of the thighs, buttocks and hips. 3)Dermatological assessment of skin tonicity of the thighs, buttocks and hips using Cellulite Severity Grading scale. 4)Dermatological assessment of under eyes dark circles using 6-point grading scale. 5)Dermatological assessment of under eye puffiness using Investigatorâ??s Global Assessment Scale. 6)Dermatological assessment of under eye fine lines using Allergan Fine Lines Scale.Timepoint: Baseline, Day 14, Day 28, Day 42, Day 56 and Day 84

Secondary

MeasureTime frame
Assessment of under eye dark circles and under eye fine lines by image analysis.Timepoint: Baseline, Day 14, Day 28, Day 42, Day 56 and Day 84;Subject Satisfaction Questionnaire and Product Response Index (Perception about Product).Timepoint: Baseline, Day 14, Day 28, Day 42, Day 56 and Day 84;6) Digital photographs of thighs, buttocks and/or hips and photographs of under eye area will be taken using Visia CRTimepoint: Baseline, Day 14, Day 28, Day 42, Day 56 and Day 84;Assessment of skin barrier function of thighs, buttocks and hips using TEWAmeter/Vapometer.Timepoint: Baseline, Day 14, Day 28, Day 42, Day 56 and Day 84;Assessment of skin elasticity of thighs, buttocks and hips using Cutometer.Timepoint: Baseline, Day 14, Day 28, Day 42, Day 56 and Day 84;Assessment of skin hydration of thighs, buttocks and hips using Corneometer/ Moisturemeter SC.Timepoint: Baseline, Day 14, Day 28, Day 42, Day 56 and Day 84

Countries

India

Contacts

Public ContactDr Simran Sethi

Cliantha Research

pjoshi@ofacto.com8000085049

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026